Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus FUNGIZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus FUNGIZONE.
AMPHOTEC vs FUNGIZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability, leading to leakage of intracellular contents and cell death.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
IV: 0.25-1 mg/kg/day as a single infusion; for aspergillosis, up to 1.5 mg/kg/day; maximum daily dose 1.5 mg/kg.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal elimination half-life is approximately 15 days (range 10-20 days) after a single dose; with prolonged therapy, a prolonged terminal half-life of up to 15 days reflects slow redistribution from tissue depots.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily fecal (40-50%) via biliary elimination without metabolism; renal excretion of unchanged drug is minimal (<5% in 24 hours).
Category C
Category C
Antifungal
Antifungal